Platelet activating factor

Platelet activating factor is a lipid of Glycerophospholipids (GP) class. Platelet activating factor is associated with abnormalities such as Atherosclerosis, Acute cholecystitis without calculus, Cholecystitis, Colitis and Cholecystitis, Acute. The involved functions are known as Cell Survival, Metabolic Inhibition, lipid oxidation, Apoptosis and Oxidation. Platelet activating factor often locates in soluble, Cellular Membrane, Smooth muscle (tissue), Intima and Tissue specimen. The associated genes with Platelet activating factor are apolipoprotein A-I Milano, Homologous Gene, TSPO gene, HBEGF gene and SLC33A1 gene. The related lipids are Hydroxycholesterols, Liposomes, 25-hydroxycholesterol, Lysophosphatidylcholines and Lipopolysaccharides. The related experimental models are Knock-out, Mouse Model and Transgenic Model.

Cross Reference

Introduction

To understand associated biological information of Platelet activating factor, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with Platelet activating factor?

Platelet activating factor is suspected in Ischemia, Pleurisy, Atherosclerosis, Inflammatory disorder, Retinal Diseases, Diabetes and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with Platelet activating factor

MeSH term MeSH ID Detail
Body Weight D001835 333 associated lipids
Lung Neoplasms D008175 171 associated lipids
Adenocarcinoma D000230 166 associated lipids
Colonic Neoplasms D003110 161 associated lipids
Edema D004487 152 associated lipids
Carcinoma, Hepatocellular D006528 140 associated lipids
Hemolysis D006461 131 associated lipids
Cell Transformation, Neoplastic D002471 126 associated lipids
Inflammation D007249 119 associated lipids
Hypertension D006973 115 associated lipids
Glioma D005910 112 associated lipids
Weight Gain D015430 101 associated lipids
Hypercholesterolemia D006937 91 associated lipids
Diabetes Mellitus D003920 90 associated lipids
Brain Ischemia D002545 89 associated lipids
Seizures D012640 87 associated lipids
Diabetes Mellitus, Type 2 D003924 87 associated lipids
Arteriosclerosis D001161 86 associated lipids
Atherosclerosis D050197 85 associated lipids
Pancreatic Neoplasms D010190 77 associated lipids
Alzheimer Disease D000544 76 associated lipids
Stomach Ulcer D013276 75 associated lipids
Leukemia D007938 74 associated lipids
Coronary Disease D003327 70 associated lipids
Colitis D003092 69 associated lipids
Melanoma D008545 69 associated lipids
Mammary Neoplasms, Experimental D008325 67 associated lipids
Liver Cirrhosis D008103 67 associated lipids
Neuroblastoma D009447 66 associated lipids
Reperfusion Injury D015427 65 associated lipids
Cystic Fibrosis D003550 65 associated lipids
Pain D010146 64 associated lipids
Dermatitis, Contact D003877 59 associated lipids
Diabetes Mellitus, Type 1 D003922 56 associated lipids
Weight Loss D015431 56 associated lipids
Nerve Degeneration D009410 53 associated lipids
Parkinson Disease D010300 53 associated lipids
Asthma D001249 52 associated lipids
Kidney Failure, Chronic D007676 51 associated lipids
Osteosarcoma D012516 50 associated lipids
Thrombosis D013927 49 associated lipids
Psoriasis D011565 47 associated lipids
Coronary Artery Disease D003324 47 associated lipids
Metabolism, Inborn Errors D008661 46 associated lipids
Metabolic Syndrome D024821 44 associated lipids
Lupus Erythematosus, Systemic D008180 43 associated lipids
Hypersensitivity, Delayed D006968 43 associated lipids
Arrhythmias, Cardiac D001145 42 associated lipids
Hyperalgesia D006930 42 associated lipids
Ischemic Attack, Transient D002546 42 associated lipids
Leukemia, Experimental D007942 42 associated lipids
Leukemia, Erythroblastic, Acute D004915 41 associated lipids
Arthritis D001168 41 associated lipids
Hypotension D007022 41 associated lipids
Zellweger Syndrome D015211 39 associated lipids
Neovascularization, Pathologic D009389 39 associated lipids
Diabetic Retinopathy D003930 39 associated lipids
Peritonitis D010538 38 associated lipids
Nervous System Diseases D009422 37 associated lipids
Lung Diseases D008171 37 associated lipids
Liver Cirrhosis, Experimental D008106 36 associated lipids
Epilepsy D004827 35 associated lipids
Infarction, Middle Cerebral Artery D020244 35 associated lipids
Fever D005334 35 associated lipids
Glomerulonephritis D005921 35 associated lipids
Anaphylaxis D000707 35 associated lipids
Acute Kidney Injury D058186 34 associated lipids
Spinal Cord Injuries D013119 34 associated lipids
Anemia, Sickle Cell D000755 34 associated lipids
Burns D002056 34 associated lipids
Memory Disorders D008569 33 associated lipids
Thyroid Neoplasms D013964 33 associated lipids
Acute Lung Injury D055371 33 associated lipids
Uremia D014511 33 associated lipids
Hypertension, Pulmonary D006976 32 associated lipids
Stroke D020521 32 associated lipids
Neurodegenerative Diseases D019636 32 associated lipids
Cardiomegaly D006332 31 associated lipids
Endometrial Neoplasms D016889 30 associated lipids
Proteinuria D011507 30 associated lipids
Vitamin E Deficiency D014811 29 associated lipids
Ventricular Remodeling D020257 28 associated lipids
Neuralgia D009437 28 associated lipids
Angina Pectoris D000787 27 associated lipids
Hyperinsulinism D006946 27 associated lipids
Brain Diseases D001927 27 associated lipids
Gastritis D005756 27 associated lipids
Gastrointestinal Hemorrhage D006471 27 associated lipids
Mammary Neoplasms, Animal D015674 27 associated lipids
Endotoxemia D019446 27 associated lipids
Nasal Polyps D009298 26 associated lipids
Encephalomyelitis, Autoimmune, Experimental D004681 26 associated lipids
Leukemia-Lymphoma, Adult T-Cell D015459 25 associated lipids
Pseudomonas Infections D011552 25 associated lipids
Ascites D001201 25 associated lipids
Cerebrovascular Disorders D002561 25 associated lipids
Cardiovascular Diseases D002318 24 associated lipids
Pulmonary Fibrosis D011658 24 associated lipids
Colitis, Ulcerative D003093 24 associated lipids
Arthritis, Experimental D001169 24 associated lipids
Per page 10 20 50 100 | Total 288

PubChem Associated disorders and diseases

What pathways are associated with Platelet activating factor

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with Platelet activating factor?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with Platelet activating factor?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with Platelet activating factor?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with Platelet activating factor?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with Platelet activating factor?

Knock-out

Knock-out are used in the study 'A cardioprotective role for platelet-activating factor through NOS-dependent S-nitrosylation.' (Leary PJ et al., 2008).

Mouse Model

Mouse Model are used in the study 'A regulatory role of LPCAT1 in the synthesis of inflammatory lipids, PAF and LPC, in the retina of diabetic mice.' (Cheng L et al., 2009).

Transgenic Model

Transgenic Model are used in the study 'Heterogeneity in the sn-1 carbon chain of platelet-activating factor glycerophospholipids determines pro- or anti-apoptotic signaling in primary neurons.' (Ryan SD et al., 2008).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with Platelet activating factor

Download all related citations
Per page 10 20 50 100 | Total 8526
Authors Title Published Journal PubMed Link
Heptinstall S and Bevan J How can we inhibit 5-HT-induced platelet aggregation and why should we bother? 1988 Folia Haematol. Int. Mag. Klin. Morphol. Blutforsch. pmid:2465956
Bodzenta-Lukaszyk A et al. Blood platelet function in patients with obliterative arteriosclerosis of the lower limbs. 1988 Folia Haematol. Int. Mag. Klin. Morphol. Blutforsch. pmid:2465957
Terashita Z et al. Protective effects of a platelet activating factor (PAF) antagonist and its combined treatment with prostaglandin (PG) E1 in traumatic shock. 1988 J. Cardiovasc. Pharmacol. pmid:2468048
Alessandrì MG et al. PAF-induced histamine release in the isolated perfused rat kidney. 1988 Int J Tissue React pmid:2456276
Martin TR et al. Pulmonary responses to bronchoconstrictor agonists in the mouse. 1988 J. Appl. Physiol. pmid:2457008
Yoshida K et al. PAF inhibitors of microbial origin. Studies on diketopiperazine derivatives. 1988 Prog Biochem Pharmacol pmid:2457219
Bachelet M et al. Interaction between PAF-acether and drugs that stimulate cyclic AMP in guinea-pig alveolar macrophages. 1988 Eur. J. Pharmacol. pmid:2840303
Lerner R et al. Platelet activating factor and leukotriene B4 induce hyperpolarization of human endothelial cells but depolarization of neutrophils. 1988 Biochem. Biophys. Res. Commun. pmid:2838025
Trovati M et al. Insulin directly reduces platelet sensitivity to aggregating agents. Studies in vitro and in vivo. 1988 Diabetes pmid:2838353
Lefort J et al. Pharmacological profile of 48740 R.P., a PAF-acether antagonist. 1988 Eur. J. Pharmacol. pmid:2843382
López-Farré A et al. Glomeruli from ischemic rat kidneys produce increased amounts of platelet activating factor. 1988 Biochem. Biophys. Res. Commun. pmid:3358756
Kuiper J et al. The induction of glycogenolysis in the perfused liver by platelet activating factor is mediated by prostaglandin D2 from Kupffer cells. 1988 Biochem. Biophys. Res. Commun. pmid:3144970
Valone FH and Epstein LB Biphasic platelet-activating factor synthesis by human monocytes stimulated with IL-1-beta, tumor necrosis factor, or IFN-gamma. 1988 J. Immunol. pmid:3141509
Anderson G and Fennessy M Effects of REV 5901, a 5-lipoxygenase inhibitor and leukotriene antagonist, on pulmonary responses to platelet activating factor in the guinea-pig. 1988 Br. J. Pharmacol. pmid:3145088
Sessler CN et al. Effects of platelet-activating factor antagonist SRI 63-441 on endotoxemia in sheep. 1988 J. Appl. Physiol. pmid:3145934
Del Monte M and Subissi A Platelet-activating factor-induced contraction of guinea-pig lung parenchymal strips: possible involvement of arachidonate metabolites. 1988 Naunyn Schmiedebergs Arch. Pharmacol. pmid:3149718
Hofmann B et al. Effects of synthetic analogues of platelet-activating factor (PAF) on fibrinolytic activity in the rat. 1988 Biomed. Biochim. Acta pmid:3150268
Bahr T et al. Influence of inhibitors of the eicosanoid metabolism, of antagonists of the eicosanoids and of PAF on mortality assayed in three biochemically characterized shock models. 1988 Biomed. Biochim. Acta pmid:3150272
O'Flaherty JT et al. Mechanism involved in the mobilization of neutrophil calcium by 5-hydroxyeicosatetraenoate. 1988 J. Immunol. pmid:2836511
Smith RJ et al. Diacylglycerols modulate human polymorphonuclear neutrophil responsiveness: effects on intracellular calcium mobilization, granule exocytosis, and superoxide anion production. 1988 J. Leukoc. Biol. pmid:2836539
Hofmann B et al. Proaggregatory and inhibitory effects of 2-O-ethyl analogues of platelet-activating factor (PAF) on human and rabbit platelets. 1988 Thromb. Res. pmid:3381200
Rao GH Measurement of ionized calcium in normal human blood platelets. 1988 Anal. Biochem. pmid:3382012
Banks JB et al. Evidence for protein-catalyzed transfer of platelet activating factor by macrophage cytosol. 1988 Biochim. Biophys. Acta pmid:3382692
Miyazawa K et al. Modulation of stimulus-dependent human platelet activation by C-reactive protein modified with active oxygen species. 1988 J. Immunol. pmid:3385211
Archer CB et al. Actions of platelet activating factor (PAF) homologues and their combinations on neutrophil chemokinesis and cutaneous inflammatory responses in man. 1988 J. Invest. Dermatol. pmid:3385217
Taylor RR et al. Time dependence of whole blood aggregation in response to platelet activating factor (PAF). 1988 Thromb. Haemost. pmid:3388292
Powling MJ and Hardisty RM Potentiation by adrenaline of Ca2+ influx and mobilization in stimulated human platelets: dissociation from thromboxane generation and aggregation. 1988 Thromb. Haemost. pmid:3388294
Pirotzky E et al. Cyclosporine-induced nephrotoxicity: preventive effect of a PAF-acether antagonist, BN 52063. 1988 Transplant. Proc. pmid:3388505
Serio R and Daniel EE Thromboxane effects on canine trachealis neuromuscular function. 1988 J. Appl. Physiol. pmid:2839451
Hellegouarch A et al. Effects of BN 52063 and other agents inhibiting platelet-activating factor-induced contractile responses in rat portal vein. 1988 J. Pharm. Pharmacol. pmid:2907020
Subissi A et al. Effects of anti-asthma drugs on PAF-induced death in mice. 1988 Prostaglandins pmid:2907663
Lima MC et al. Mediators of inflammation and antagonism of experimental pleurisy in the rat by fenspiride. 1988 Rhinol. Suppl. pmid:2907679
Smith LJ et al. Mechanism of platelet activating factor-induced bronchoconstriction in humans. 1988 Am. Rev. Respir. Dis. pmid:3195800
O'Neill C et al. Embryo-derived platelet-activating factor. Its diagnostic and therapeutic future. 1988 Ann. N. Y. Acad. Sci. pmid:3195924
Roberts NM et al. Effect of a PAF antagonist, BN52063, on antigen-induced, acute, and late-onset cutaneous responses in atopic subjects. 1988 J. Allergy Clin. Immunol. pmid:3403863
Ninio E et al. Biosynthesis of paf-acether. XI. Regulation of acetyltransferase by enzyme-substrate imbalance. 1988 Biochim. Biophys. Acta pmid:3196734
Hsueh W and Gonzalez-Crussi F Ischemic bowel necrosis induced by platelet-activating factor: an experimental model. 1988 Methods Achiev Exp Pathol pmid:3045496
Kumar R et al. Production and effects of platelet-activating factor in the rat brain. 1988 Biochim. Biophys. Acta pmid:3196741
Braquet P et al. Effects of the specific platelet-activating factor antagonists, BN 52021 and BN 52063, on various experimental gastrointestinal ulcerations. 1988 Eur. J. Pharmacol. pmid:3046952
Bette-Bobillo P and Bienvenue A Platelet-activating-factor-induced serum-albumin release from rabbit platelets in the absence of calcium. 1988 Eur. J. Biochem. pmid:3197724
Barr R et al. The effect of platelet activating factor on electron transport of spinach chloroplasts. 1988 Biochem. Biophys. Res. Commun. pmid:3048258
Cueva JP and Hsueh W Role of oxygen derived free radicals in platelet activating factor induced bowel necrosis. 1988 Gut pmid:3197995
Camussi G et al. Synthesis and release of platelet-activating factor is inhibited by plasma alpha 1-proteinase inhibitor or alpha 1-antichymotrypsin and is stimulated by proteinases. 1988 J. Exp. Med. pmid:3049910
Bass DA et al. Selective priming of rate and duration of the respiratory burst of neutrophils by 1,2-diacyl and 1-O-alkyl-2-acyl diglycerides. Possible relation to effects on protein kinase C. 1988 J. Biol. Chem. pmid:3198643
Cahill M et al. Effect of des arginine9-bradykinin and other bradykinin fragments on the synthesis of prostacyclin and the binding of bradykinin by vascular cells in culture. 1988 Agents Actions pmid:3051930
Lewis MS et al. Hydrogen peroxide stimulates the synthesis of platelet-activating factor by endothelium and induces endothelial cell-dependent neutrophil adhesion. 1988 J. Clin. Invest. pmid:3198764
Page CP et al. Drugs affecting pulmonary responses to platelet activating factor as novel anti-asthma drugs. 1988 Agents Actions Suppl. pmid:3051932
Fukuoka T et al. [Effect of a platelet activating factor (PAF) antagonist on the hepatic afferent vascular occlusion]. 1988 Nihon Geka Gakkai Zasshi pmid:3412312
Makino S [Platelet activating factor in allergic reaction]. 1988 Arerugi pmid:3052368
Janero DR et al. Specific binding of 1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine (platelet-activating factor) to the intact canine platelet. 1988 Thromb. Res. pmid:3413730
Wasserman SI Platelet-activating factor as a mediator of bronchial asthma. 1988 Hosp. Pract. (Off. Ed.) pmid:3053741
Altman R et al. Diltiazem potentiates the inhibitory effect of aspirin on platelet aggregation. 1988 Clin. Pharmacol. Ther. pmid:3416553
Chu KM et al. Local vasodilator effect of platelet activating factor in the gastric, mesenteric and femoral arteries of the dog. 1988 J. Pharmacol. Exp. Ther. pmid:3418522
Pai JK et al. Activation of phospholipase D by chemotactic peptide in HL-60 granulocytes. 1988 Biochem. Biophys. Res. Commun. pmid:3422154
Morrison WJ and Shukla SD Desensitization of receptor-coupled activation of phosphoinositide-specific phospholipase C in platelets: evidence for distinct mechanisms for platelet-activating factor and thrombin. 1988 Mol. Pharmacol. pmid:2827000
Steel LK et al. Quantitative, functional and biochemical alterations in the peritoneal cells of mice exposed to whole-body gamma-irradiation. I. Changes in cellular protein, adherence properties and enzymatic activities associated with platelet-activating factor formation and inactivation, and arachidonate metabolism. 1988 Int. J. Radiat. Biol. Relat. Stud. Phys. Chem. Med. pmid:3286551
Barnes PJ et al. Platelet-activating factor as a mediator of allergic disease. 1988 J. Allergy Clin. Immunol. pmid:3286723
Benveniste J Paf-acether, an ether phospho-lipid with biological activity. 1988 Prog. Clin. Biol. Res. pmid:3071808
Nakayama R and Saito K [PAF and its physiological significance in normal tissue]. 1988 Seikagaku pmid:3286791
Dulioust A et al. Immunoregulatory functions of paf-acether (platelet-activating factor). 1988 Prog. Clin. Biol. Res. pmid:3071809
Chung KF et al. Ketotifen inhibits the cutaneous but not the airway responses to platelet-activating factor in man. 1988 J. Allergy Clin. Immunol. pmid:3288683
Lee TC et al. Formation of 1-alkyl-2-acetyl-sn-glycerols via the de novo biosynthetic pathway for platelet-activating factor. Characterization of 1-alkyl-2-acetyl-sn-glycero-3-phosphate phosphohydrolase in rat spleens. 1988 J. Biol. Chem. pmid:2828351
Romero A et al. [Effect of corticosteroids, quinacrine and L-652, 731 on experimental aggregation of polymorphonuclear leukocytes induced by complement and platelet activating factor (PAF)]. 1988 Rev. Esp. Fisiol. pmid:3072620
Page CP and Robertson DN The role of PAF in altered airway responsiveness. 1988 Prog. Clin. Biol. Res. pmid:3289016
Nieto ML et al. Biosynthesis of platelet-activating factor in human polymorphonuclear leukocytes. Involvement of the cholinephosphotransferase pathway in response to the phorbol esters. 1988 J. Biol. Chem. pmid:2828363
Arnout J et al. Effectiveness and tolerability of CV-3988, a selective PAF antagonist, after intravenous administration to man. 1988 Br J Clin Pharmacol pmid:3289599
Ponpipom MM et al. (+/-)-trans-2-(3-Methoxy-5-methylsulfonyl-4-propoxyphenyl)-5-(3,4,5- trimethoxyphenyl)tetrahydrofuran (L-659,989), a novel, potent PAF receptor antagonist. 1988 Biochem. Biophys. Res. Commun. pmid:2829894
Braquet P et al. Platelet activating factor as a mediator in cerebral ischemia and related disorders. 1988 Biomed. Biochim. Acta pmid:3073761
O'Donnell SR and Barnett CJ pA2 values for antagonists of platelet activating factor on aggregation of rabbit platelets. 1988 Br. J. Pharmacol. pmid:3293683
Giovannini L et al. N-acetyl-beta-glucosaminidase (NAG) and alpha-glycosidase released by PAF in isolated perfused rat kidney. 1988 Int J Tissue React pmid:3294206
Esplugues JV and Whittle BJ Gastric mucosal damage induced by local intra-arterial administration of Paf in the rat. 1988 Br. J. Pharmacol. pmid:3349230
Kobayashi T et al. Metabolism and disposition of (RS)-2-methoxy-3-(octadecylcarbamoyloxy)propyl 2-(3-thiazolio)ethyl phosphate (MOTP) in rats and dogs. 1988 Xenobiotica pmid:3354232
Arnoux B et al. Accumulation of platelets and eosinophils in baboon lung after paf-acether challenge. Inhibition by ketotifen. 1988 Am. Rev. Respir. Dis. pmid:3354991
Nakayama R et al. 1-O-hexadec-1'-enyl-2-acetyl-sn-glycero-3-phosphocholine and its biological activity. 1988 Biochem. Biophys. Res. Commun. pmid:3355555
Kramer RM et al. Hydrolysis of 1-alkyl-2-arachidonoyl-sn-glycero-3-phosphocholine, a common precursor of platelet-activating factor and eicosanoids, by human platelet phospholipase A2. 1988 Biochim. Biophys. Acta pmid:3355850
McGowan HM et al. Increased levels of platelet-activating factor (1-O-alkyl-2-acetylglycerophosphocholine) in blood after reversal of renal clip hypertension in the rat. 1988 Clin. Sci. pmid:3356112
Quinn MT et al. Lysophosphatidylcholine: a chemotactic factor for human monocytes and its potential role in atherogenesis. 1988 Proc. Natl. Acad. Sci. U.S.A. pmid:3357891
Leslie CC et al. Properties and purification of an arachidonoyl-hydrolyzing phospholipase A2 from a macrophage cell line, RAW 264.7. 1988 Biochim. Biophys. Acta pmid:3143418
Kosano H and Takatani O Reduction of epidermal growth factor binding in human breast cancer cell lines by an alkyl-lysophospholipid. 1988 Cancer Res. pmid:3262419
Berstad A et al. Effect of platelet-activating factor and its receptor antagonist, SRI 63-675, on gastric bleeding in rats. 1988 Scand. J. Gastroenterol. pmid:3262915
Morley J et al. Pharmacological evaluation of prophylactic anti-asthma drugs by reference to the pathological sequelae of exposure to allergen or platelet activating factor. 1988 Agents Actions Suppl. pmid:3262989
Subissi A and Criscuoli M Effects of LG 30435 on different platelet activating factor-induced responses. 1988 Agents Actions Suppl. pmid:3262990
Heuer H and Casals-Stenzel J Effect of the PAF-antagonist WEB 2086 on anaphylactic lung reaction: comparison of inhalative and intravenous challenge. 1988 Agents Actions Suppl. pmid:3262991
Ontell SJ et al. Improved hepatic function in the 24-hour preserved rat liver with UW-lactobionate solution and SRI 63-441. 1988 Gastroenterology pmid:3263295
Eliakim R et al. Role of platelet-activating factor in ulcerative colitis. Enhanced production during active disease and inhibition by sulfasalazine and prednisolone. 1988 Gastroenterology pmid:2901995
Breviario F et al. IL-1-induced adhesion of polymorphonuclear leukocytes to cultured human endothelial cells. Role of platelet-activating factor. 1988 J. Immunol. pmid:3263425
Page CP The role of platelet-activating factor in asthma. 1988 J. Allergy Clin. Immunol. pmid:3276759
Barnes PJ Platelet-activating factor and asthma. 1988 J. Allergy Clin. Immunol. pmid:3276760
Haynes J et al. Platelet-activating factor antagonists increase vascular reactivity in perfused rat lungs. 1988 J. Appl. Physiol. pmid:3209541
Ryan US et al. Influence of vasoactive agents on cytoplasmic free calcium in vascular endothelial cells. 1988 J. Appl. Physiol. pmid:3209566
Nogami M et al. [Effects of a platelet activating factor (PAF) antagonist CV-3988 on acute gastric erosions in rats by water immersion and restrained stress, and by ethanol]. 1988 Nihon Shokakibyo Gakkai Zasshi pmid:3210345
Schwertschlag US et al. Nonimmunological alterations of glomerular filtration by s-PAF in the rat kidney. 1988 Kidney Int. pmid:3210538
Fisher RA et al. AGEPC: a potent calcium-dependent chemical mediator in the liver. 1988 Adv. Exp. Med. Biol. pmid:3213685
Mickelson JK et al. Myocardial dysfunction and coronary vasoconstriction induced by platelet-activating factor in the post-infarcted rabbit isolated heart. 1988 J. Mol. Cell. Cardiol. pmid:3216407
Bussolino F [Production of PAF (1-0-alkyl-2-acetyl-sn-glycero-3-phosphocholine) in the chick retina during embryogenesis]. 1988 Ann. Ist. Super. Sanita pmid:3218801
Dillon PK et al. Effect of platelet-activating factor on leukocyte adhesion to microvascular endothelium. Time course and dose-response relationships. 1988 Inflammation pmid:3220518
van Delft JL et al. Specific receptor sites for PAF in iris and ciliary body of the rabbit eye. 1988 Curr. Eye Res. pmid:2854038
Lohmann HF et al. Idiopathic thrombocytopenia treated with Paf-acether antagonist WEB 2086. 1988 Lancet pmid:2903365
Shirinsky VP et al. Agonist-induced polyphosphoinositide breakdown in cultured human endothelial and vascular smooth muscle cells. 1988 Health Psychol pmid:2854052
Colton CA and Gilbert DL An endogenous source of the superoxide anion in the central nervous system. 1988 Basic Life Sci. pmid:2854971